Amgen (AMGN) tops profit expectations, revenue rises 5%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amgen sales rise, but shares off as investors await obesity data
October 31, 2023 7:10 AM EDTBy Deena Beasley
(Reuters) -Amgen on Tuesday said third-quarter sales rose 5%, but a full-year sales forecast raise only reflected additional revenue from its $27.8 billion acquisition this month of Horizon Therapeutics and its shares fell nearly 4%.
Sales of some high profile medicines also fell short of expectations, likely contributing to the share move.
Amgen said it expects to announce findings from an early-stage trial of experimental obesity pill AMG786 in the first half of next year, and to have results from a mid-stage trial of a different, injected obesity candidate, AMG133, by late next year.
"Overall... More
Amgen (AMGN) Tops Q3 EPS by 28c; Raises Outlook
October 31, 2023 7:03 AM EDTAmgen (NASDAQ: AMGN) reported Q3 EPS of $4.96, $0.28 better than the analyst estimate of $4.68. Revenue for the quarter came in at $6.9 billion versus the consensus estimate of $6.92 billion.
GUIDANCE:
Amgen sees FY2023 EPS of $18.20-$18.80, versus the consensus of $17.31. Amgen sees... More
Amgen (AMGN) PT Raised to $272 at UBS
October 30, 2023 9:21 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $272.00 (from $260.00) while maintaining a Neutral rating.... More
